InnovAge (INNV) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
First quarter fiscal 2025 revenues reached $205.1 million, up 12.4% year-over-year, with Adjusted EBITDA of $6.5 million, a 500% increase year-over-year and margin improving to 3.2%.
Net loss narrowed to $5.7 million from $11 million year-over-year, with net loss margin improving to 2.8% from 6.0%.
Participant census increased to approximately 7,210, up 10% year-over-year, reflecting improved sales, marketing, and operational execution.
Leadership transition included the appointment of a new President and COO, Michael Scarbrough, bringing extensive healthcare experience.
Served approximately 7,210 PACE participants across 20 centers in six states as of September 30, 2024, maintaining status as the largest PACE provider in the U.S.
Financial highlights
Total revenues were $205.1 million, up 12.4% year-over-year, driven by higher member months and increased capitation rates.
Center-level contribution margin increased to $34.5 million (16.8% of revenue), up from $27.9 million (15.3%).
Net loss narrowed to $5.7 million from $11 million year-over-year; Adjusted EBITDA margin improved to 3.2% from 0.7%.
Ended the quarter with $39 million in cash, $46.7 million in short-term investments, and $81.3 million in total debt.
Operating loss improved to $4.9 million from $10.7 million year-over-year.
Outlook and guidance
Fiscal 2025 guidance: revenue between $815 million and $865 million; Adjusted EBITDA between $24 million and $31 million.
Participant census expected between 7,300 and 7,750; total member months between 86,000 and 89,000.
De novo losses for fiscal 2025 expected in the $18–$20 million range.
Growth expected to be linear with some seasonal slowdown in Q3; financial impact of member month growth weighted toward the back half of the year.
Expect continued elevated operating expenses in fiscal 2025 due to census growth and labor costs, but anticipate clinical and operational initiatives will help offset cost pressures.
Latest events from InnovAge
- Registering 112.99M shares for resale by holders; largest PACE provider with recurring revenue.INNV
Registration filing - Integrated care model for complex seniors drives growth, margin expansion, and superior outcomes.INNV
Corporate presentation - Revenue and margins rose 15.5%, but net loss increased due to litigation and compliance costs.INNV
Q3 2026 - Integrated care model drives growth, margin expansion, and superior outcomes for complex seniors.INNV
Corporate presentation - Q2 revenue and margins surged, raising full-year guidance despite ongoing cost and regulatory risks.INNV
Q2 2026 - Integrated care model and tech investments drive growth, margin gains, and superior outcomes.INNV
44th Annual J.P. Morgan Healthcare Conference - Care coordination, trust, and tailored technology are key to advancing aging-in-place models.INNV
7th Annual Healthcare Symposium - Revenue up 11% with margin gains and positive Adjusted EBITDA; 2025 outlook remains strong.INNV
Q4 2024 - Revenue up 13% but net loss widened; Adjusted EBITDA and 2025 guidance improved.INNV
Q3 2025